Navigation Links
Mylan Receives Approval for Generic Version of Zinecard® for Injection
Date:11/28/2011

PITTSBURGH, Nov. 28, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its business Mylan Institutional has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Dexrazoxane for Injection, packaged in 250 mg and 500 mg Single-use Vials. This product is the generic version of Pharmacia & Upjohn's Zinecard® for Injection, a chemoprotective agent.

Dexrazoxane for Injection, when indicated for the same use as Zinecard for Injection, had U.S. sales of approximately $3.4 million for the 12 months ending Sept. 30, 2011, according to IMS Health. Mylan Institutional is shipping this product immediately.   

Currently, Mylan has 161 ANDAs pending FDA approval representing $97.7 billion in annual sales, according to IMS Health. Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $26.9 billion in annual brand sales, for the 12 months ending June 30, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit http://www.mylan.com/. For more information about generic drugs, please visit http://www.choosinggenerics.com/.

 

 

 

 

 

 

 


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
2. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
3. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
4. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
5. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
6. Mylan Receives Approval for Generic Version of GoLytely(R)
7. Mylan Declares Quarterly Preferred Stock Dividend
8. Mylan Pre-Pays All Scheduled 2011 Term-Loan Borrowings
9. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
10. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
11. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today ... ended December 31, 2014 on March 9, 2015. The Company also ... Thursday, March 12, 2015, at 5:00 pm ET. The call will ...   , , , LIVE CALL:  , ... 92238648. , , , , ...
(Date:3/1/2015)... , March 1, 2015 /CNW Telbec/ -   Ergoresearch Ltd ... and known under the « Équilibre, ... the second quarter Ended on December 31, 2014. All ... currency. Revenues for the second quarter ... 2014 totaled $ 4 095 112 decreasing by 8,8 % compared to ...
(Date:3/1/2015)...  USPlabs has notified the Food and Drug ... media reports saying that a company product contains ... 28, 2015, the Center for Drug Evaluation and ... contamination of a dietary supplement product labeled as ... "OEP") with a prescription drug active ingredient, fluoxetine. ...
Breaking Medicine Technology:ImmunoCellular Therapeutics to Report 2014 Financial Results on March 9, 2015; a Business Update Conference Call and Webcast is Scheduled for March 12, 2015 2Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 2Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 3Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 4OEP Product Is Counterfeit 2
... TEL-AVIV, Israel , March 15, 2010 Cheetah Medical, a,worldwide leader in noninvasive hemodynamic and cardiac output ... and also included Robert,Bosch Venture Capital (RBVC), MVM Life Science Partners (MVM) and existing,investors. , ... ... ...
... With heart disease continuing to be the No. 1 cause of death in the U.S., Atherotech Inc. has ... company is expanding its disease management services with the goal of helping physicians reduce death and disability from heart disease. ... ... , ...
Cached Medicine Technology:Cheetah Medical Closes $20 Million Series B Financing 2Cheetah Medical Closes $20 Million Series B Financing 3Cheetah Medical Closes $20 Million Series B Financing 4Cheetah Medical Closes $20 Million Series B Financing 5Cheetah Medical Closes $20 Million Series B Financing 6Atherotech Recruits Top Experts in Fight Against Heart Disease 2Atherotech Recruits Top Experts in Fight Against Heart Disease 3Atherotech Recruits Top Experts in Fight Against Heart Disease 4Atherotech Recruits Top Experts in Fight Against Heart Disease 5Atherotech Recruits Top Experts in Fight Against Heart Disease 6
(Date:3/2/2015)... Minneapolis, Minnesota (PRWEB) March 02, 2015 ... a new strategic relationship with First Protective Insurance ... new initiative will allow First Protective affiliated advisors ... and implementation support that Secura Consultants delivers. ... is a national leader in the design and ...
(Date:3/1/2015)... Excellence is pleased to announce the addition of a digital ... are over 75 terms and phrases available for viewing, with more ... patients a better understanding of what our Providers are talking about ... With this resource, our patients are able to go back to ... that they may not remember or comprehend at the time of ...
(Date:3/1/2015)... Researchers say working around asbestos-containing construction products may ... contract malignant mesothelioma. Surviving Mesothelioma has just posted the ... Click here to read it now. , Scientists ... 17,345 sheet metal workers from 1986 to 2010 and ... mesothelioma or another asbestos-related disease . , “Significant ...
(Date:3/1/2015)... (PRWEB) March 01, 2015 Indiana ... Network Service Provider, announces NewWays Networking, LLC (NewWays) ... “By working with IFN, NewWays is well positioned ... client’s demand for Internet bandwidth in rural parts ... , According to Cory Childs IFN Enterprise Sales ...
(Date:3/1/2015)... CrossFit Attollo is a CrossFit gym located in Vancouver ... to new members. Now through the end of March ... will receive their fourth month half off. , ... The three month contract is only $264, dropping the price ... comes in at only $55. The special saves new members ...
Breaking Medicine News(10 mins):Health News:Secura Consultants and First Protective Insurance Group Announce Strategic Relationship 2Health News:New Study Finds Indirect Asbestos Exposure Can Raise Mesothelioma Risk for Sheet Metal Workers, According to Surviving Mesothelioma 2Health News:NewWays Networking Selects Indiana Fiber Network, LLC as Fiber Transport Provider 2Health News:CrossFit Gym in Vancouver WA Offers Spring Special 2
... "As a physician,you hear all sorts of excuses ... Hashey, Medical Director of First Coast Family Medicine and ... most common that Dr. Hashey reports is the excuse ... "That couldn,t be farther from the truth.,The flu shot ...
... for ... Cardiac Rehabilitation, BOTHELL, Wash., ... global leader in advanced cardiac monitoring,and defibrillation products, announced today ... has seamless connectivity with LUMEDX,CardioWellness(TM) data management software. (Logo: ...
... patient outcomes at Houston Northwest Medical ... among nation,s best for several service lines, ... Annual,HealthGrades Hospital Quality in America Study issued today, ... several service,lines including overall gastrointestinal services, gastrointestinal,surgery, stroke, ...
... Oct. 17 /PRNewswire/ - The numbers are staggering --,over ... have a,disability. "It,s not the impairment or disability ... their exclusion from mainstream,social, economic and political opportunities," says ... have to work together to stand up and speak ...
... methicillin-resistant Staphylococcus aureus Infections in the, United States, shows that hospital-caused MRSA ... and Prevention have,consistently understated the size of the problem and have failed ... protect patients from these ... infections., NEW ...
... hold a press availability tomorrow, Wednesday, October 17, at 10:30,a.m. ... 2-year-old,from Tampa, Fla., who was born with a serious heart ... is on Capitol Hill urging Members of,Congress to vote to ... 10 million children., WHO: Speaker Nancy ...
Cached Medicine News:Health News:Flu Myths Abound in Flu Season 2Health News:Cardiac Science Announces Data Connectivity with LUMEDX 2Health News:Cardiac Science Announces Data Connectivity with LUMEDX 3Health News:Cardiac Science Announces Data Connectivity with LUMEDX 4Health News:Houston Northwest Medical Center's Patient Outcomes Superior 2Health News:Houston Northwest Medical Center's Patient Outcomes Superior 3Health News:CBM USA stands up and speaks out to world leaders on the International Day for the Eradication of Poverty 2Health News:The Journal of the American Medical Association (JAMA) Article Reveals Scope of MRSA Infections 2
For injecting viscoelastic to all meridians of the anterior chamber and to coat intraocular lenses. 20G x 7.8in (.90 x 22mm)....
For administering anesthetic agents into the posterior sub-Tenon's space 20G x 1in (.90 x 25mm)...
... most versatile diagnostic tool in the eye ... glaucoma, diabetic retinopathy, age-related macular degeneration and ... the only system in the market that ... the optic nerve areas in one session, ...
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Medicine Products: